Research Center for Good Practice in TCM Proessing Technology, Guangdong Pharmaceutical University, Guangzhou 510006, China; The College of Traditional Chinese Medicine, Guangdong Pharmaceutical University, Guangzhou 510006, China; Pharmacy College, Heilongjiang University of Chinese Medicine, Harbin 150040, China.
Research Center for Good Practice in TCM Proessing Technology, Guangdong Pharmaceutical University, Guangzhou 510006, China.
Phytomedicine. 2020 Nov;78:153288. doi: 10.1016/j.phymed.2020.153288. Epub 2020 Jul 22.
Timosaponin BⅡ (TBⅡ), one of the primary bioactive compounds from Anemarrhena asphodeloides Bunge, possesses potential cardioprotective effects. However, the mechanism underlying TBⅡ-mediated cardioprotection, especially the involvement of endoplasmic reticulum stress, remains largely unknown.
This study was designed to evaluate the role of TBⅡ in myocardial injury protection and explore its possible mechanisms.
In vivo models of isoproterenol-induced myocardial injury and HO-induced cytotoxicty were established to investigate the effect of anti-myocardial injury of TBⅡ. The potential mechanisms were investigated in vitro and in vivo using multiple detection methods like electrocardiography, histo-pathological examination, JC-1 staining, TUNEL staining, ELISA technology, and western blot analysis.
In vivo study revealed that TBⅡ improved electrocardiography and heart vacuolation, reduced myocyte apoptosis, and improved the antioxidant potential. In vitro investigation demonstrated that TBⅡ pretreatment inhibited ER stress-mediated apoptosis pathways. Further investigation of the underlying mechanisms revealed that TBⅡ prevented HO-induced H9c2 cardiomyocytes injury by the PI3K/Akt pathways, whereas the addition of LY294002, the pharmacologic antagonist of PI3K, attenuated TBⅡ-induced expression of apoptotic protein and cytoprotective effects.
These results suggested that TBⅡ protects against myocardial injury in vitro and enhances cellular defense capacity by inhibiting ER stress-mediated apoptosis pathways in vivo by activating the PI3K/Akt pathways.
知母皂苷 BⅡ(TBⅡ)是知母中的主要生物活性化合物之一,具有潜在的心脏保护作用。然而,TBⅡ介导的心脏保护作用的机制,特别是内质网应激的参与,在很大程度上仍不清楚。
本研究旨在评估 TBⅡ在心肌损伤保护中的作用,并探讨其可能的机制。
建立异丙肾上腺素诱导的心肌损伤和 HO 诱导的细胞毒性模型,以研究 TBⅡ的抗心肌损伤作用。采用心电图、组织病理学检查、JC-1 染色、TUNEL 染色、ELISA 技术和 Western blot 分析等多种检测方法,在体外和体内研究潜在机制。
体内研究表明,TBⅡ改善了心电图和心肌空泡化,减少了心肌细胞凋亡,提高了抗氧化能力。体外研究表明,TBⅡ预处理抑制了 ER 应激介导的细胞凋亡途径。进一步的机制研究表明,TBⅡ通过 PI3K/Akt 通路防止 HO 诱导的 H9c2 心肌细胞损伤,而 PI3K 的药理学拮抗剂 LY294002 削弱了 TBⅡ诱导的凋亡蛋白表达和细胞保护作用。
这些结果表明,TBⅡ通过激活 PI3K/Akt 通路抑制 ER 应激介导的细胞凋亡途径,在体内保护体外心肌损伤并增强细胞防御能力。